LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for their performance, quality and range.
LGC’s tools play a key role in customer workflows from discovery applications through to commercial manufacture and enable its customers to: bring new diagnostics and therapies to market; progress research and development; optimise food production; and continuously monitor and enhance the quality of food, the environment and consumer products.
LGC’s 175+ years of scientific heritage, combined with a track record of innovation and value-enhancing acquisitions, has enabled the company to build its product portfolio and expertise, and develop deep relationships with customers, industry partners and the global scientific community.
LGC’s core purpose of Science for a safer world and its core values of passion, curiosity, integrity, brilliance and respect, drive its culture. As of 30 June 2021, it employs 4,350 employees, of which over 1,175 employees hold PhD and/or master’s degrees. Its products and services are delivered by highly qualified and experienced teams, operating from a global network of accredited sites that showcase its scientific and manufacturing capabilities.
LGC’s tools play a key role in customer workflows from discovery applications through to commercial manufacture and enable its customers to: bring new diagnostics and therapies to market; progress research and development; optimise food production; and continuously monitor and enhance the quality of food, the environment and consumer products.
LGC’s 175+ years of scientific heritage, combined with a track record of innovation and value-enhancing acquisitions, has enabled the company to build its product portfolio and expertise, and develop deep relationships with customers, industry partners and the global scientific community.
LGC’s core purpose of Science for a safer world and its core values of passion, curiosity, integrity, brilliance and respect, drive its culture. As of 30 June 2021, it employs 4,350 employees, of which over 1,175 employees hold PhD and/or master’s degrees. Its products and services are delivered by highly qualified and experienced teams, operating from a global network of accredited sites that showcase its scientific and manufacturing capabilities.
Location: United Kingdom, England, Teddington
Employees: 1001-5000
Founded date: 1842
Investors 2
| Date | Name | Website |
| - | Cinven | cinven.com |
| - | Kohlberg K... | kkr.com |
Mentions in press and media 9
| Date | Title | Description |
| 21.07.2026 | Low-cost 3D printed sensors could widen access to diagnostics | A team at the University of Brighton is building a new class of inexpensive, environmentally conscious medical sensors that aim to make testing cheaper and more widely available. Over the past three years, researchers under Professor Bhavik... |
| 16.07.2026 | Bridgepoint To Acquire Majority Stake In GBA Group From Ardian | Bridgepoint, a London-based mid-market private equity firm, has agreed to acquire a majority stake in GBA Group, a Hamburg-headquartered laboratory testing company and one of the largest laboratory-centric testing, inspection, and certifica... |
| 16.07.2026 | Laboratory Proficiency Testing Market Driven by Increasing Demand for Accurate Diagnostic Results | The Laboratory Proficiency Testing Market was valued at USD 1.53 Bn. in 2025. The Global Laboratory Proficiency Testing Market size is estimated to grow at a CAGR of 6.3% from 2026-2032, reaching USD 2.34 Bn by 2032. Laboratory Proficiency ... |
| 02.12.2024 | FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians | Agreement Enables Clinical Researchers to Access Breakthrough Technology for Neurologic Diseases CORALVILLE, Iowa–(BUSINESS WIRE)–December 2, 2024– FBB Biomed today announced it has signed a Master Services Agreement with Verici Dx plc (AIM... |
| 22.04.2021 | The Native Antigen Company launches SARS-CoV-2 Neutralisation Assay Development Kit | Kit enables identification and qualitative measurement of neutralising antibodies to support characterisation of SARS-CoV-2 variants and monitoring of vaccine efficacy. Oxford, UK...The Native Antigen Company, part of LGC Clinical Diagnosti... |
| 22.04.2021 | The Native Antigen Company launches SARS-CoV-2 Neutralisation Assay Development Kit | The Native Antigen Company launches SARS-CoV-2 Neutralisation Assay Development Kit 22-04-2021 Kit enables identification and qualitative measurement of neutralising antibodies to support characterisation of SARS-CoV-2 variants and monitori... |
| 09.07.2020 | Mercia sells stake in biotech EIS portfolio business spun out from the University of Birmingham | Specialist asset manager, Mercia Asset Management PLC, has sold its stake in The Native Antigen Company, a leading producer of infectious disease reagents, to global life sciences tools company LGC. The sale of The Native Antigen Company is... |
| 22.03.2018 | Launch of world’s first fingerprint-based drug use confirmation test | Launch of world’s first fingerprint-based drug use confirmation test 22-03-2018 Intelligent Fingerprinting has launched the world’s first fingerprint-based drug use confirmation test. The test has been fully validated by independent testing... |
| 16.06.2014 | Horizon Discovery and LGC awarded grant for next generation cancer diagnostics | Horizon Discovery and LGC awarded grant for next generation cancer diagnostics 16-06-2014 Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies. Horizon... |